Inhaled drug combo aims to ease Heart-Lung bypass weaning

NCT ID NCT05450328

Recruiting now Disease control Sponsor: Montreal Heart Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving two inhaled drugs (milrinone and epoprostenol) before heart-lung bypass can prevent difficult separation from the machine. About 141 adults having heart surgery will be randomly assigned to receive the drug combo or a placebo. The goal is to see if the treatment reduces the need for extra heart support after bypass.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: inhaled milrinone and epoprostenol
What this could lead to: If successful, this could provide a safer way to manage pulmonary hypertension and right heart failure during heart surgery, reducing complications.
What could go wrong: This is a phase 2 trial with only 141 participants, so results are preliminary. The drugs are not yet approved by Health Canada for this use, and side effects or lack of benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure pulmonary hypertension Ventricular Dysfunction, Right

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RIGHT HEART FAILURE RIGHT VENTRICULAR DYSFUNCTION

Contacts and locations

Locations

Montreal Heart Institute
RECRUITING

Montreal, Quebec, H1T 1C8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.